Altimmune, Inc.

Based in Gaithersburg, Maryland, Altimmune is a clinical-stage biopharmaceutical company developing pharmaceutical treatments for obesity, metabolic disorders, and liver diseases. The company's primary focus is pemvidutide, a GLP-1/glucagon dual receptor agonist currently in Phase 3 clinical trials for obesity and metabolic associated steatohepatitis (MASH). This dual-mechanism approach targets both glucose metabolism and weight regulation pathways.

The company operates as a development-stage enterprise with a lean operational structure of 59 full-time employees. Altimmune has not yet generated product revenue and relies on capital from equity and debt markets to fund clinical trials and operations. Founded in 1997, the company is incorporated in Delaware and trades on the Nasdaq exchange with a market capitalization of approximately $0.5 billion.

The company's commercial strategy centers on advancing pemvidutide through late-stage clinical development, with the therapeutic potential spanning two significant markets: chronic weight management and MASH treatment. Geographic focus remains primarily in the United States, where the company operates its headquarters and research operations.